Clinical Trials Logo

Hemophilia A clinical trials

View clinical trials related to Hemophilia A.

Filter by:

NCT ID: NCT04206033 Completed - Osteopenia Clinical Trials

Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins

BOHEM
Start date: November 29, 2019
Phase:
Study type: Observational

The investigators propose, as part of the study, to carry out for each patient: - An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115, CCR2, CX3CR1, CD163 and CD206). - A population assessment of Myeloid-Derived Suppressor Cells (MDSC). - Assays of cytokines and chemokines involved in inflammation by multiplex analyzes: Il-1 (α and β), Il-4, Il-6, Il-10, Il-13, TNF- α, TGF- β, CRP , leptin, IFN- β. - Specialized dosages of proteins involved in bone metabolism. RANKL, osteoprotegerin, M-CSF, TRAPCP5.

NCT ID: NCT04205188 Completed - Haemophilia Clinical Trials

The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients.

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

this study evaluates the effects of therapeutic exercises on kinesiophobia and health-related quality of life in adult haemophilia patients. half of participants will receive therapeutic exercises and verbal information about the positive effects of therapeutic exercises on physical pathologies due to hemophilic arthropathy while the other half will receive only verbal information.

NCT ID: NCT04204408 Completed - Healthy Volunteers Clinical Trials

A Research Study Investigating Mim8 in People With Haemophilia A

FRONTIER1
Start date: January 10, 2020
Phase: Phase 2
Study type: Interventional

This study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected with a thin needle in the skin of the stomach, using a pen-injector. The study will last for up to 44 months. It consists of a main phase (part 1 and part 2) and an extension phase. In part 1, participants will be injected only once with either Mim8 or a "dummy" medicine (placebo) - which one will be decided by chance. In part 2 and the extension phase participants will get an Mim8 injection weekly or monthly.

NCT ID: NCT04188639 Completed - Clinical trials for Hemophilia A, Acquired

Emicizumab in Acquired Hemophilia A

Start date: March 23, 2021
Phase: Phase 2
Study type: Interventional

This study is an international, multicenter, open-label, single arm, prospective clinical trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

NCT ID: NCT04181697 Completed - Clinical trials for Hemophilia A Without Inhibitor

HemFitBit, an Observational Study of Physical Activity in People With Moderate and Severe Haemophilia A

Start date: November 5, 2019
Phase:
Study type: Observational

The study aims to describe physical activity (PA) levels in young people with haemophilia A in Norway compared with non-haemophilia controls, and to identify factors influencing PA. This will be conducted through an observational study measuring PA over 12 weeks. Forty young people with moderate and severe haemophilia A will be enrolled. PA data will be compared to demographically and seasonally matched non-haemophilia controls. PA will be measured using the activity tracker Fitbit Charge 3. A subgroup of participants will also wear the hip-worn accelerometer ActiGraph GTX+BT for seven consecutive days in order to validate the two devices against each other.

NCT ID: NCT04165135 Completed - Haemophilia A Clinical Trials

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment

POWER
Start date: February 24, 2020
Phase:
Study type: Observational

This multicenter, non-interventional, prospective study will collect information about activity status, bleeds, health-related quality of life (HRQoL), health status, and safety in participants with moderate or severe haemophilia A without factor VIII (FVIII) inhibitors, who are being treated in accordance with normal clinical practice.

NCT ID: NCT04161495 Completed - Clinical trials for Factor VIII Deficiency

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

XTEND-1
Start date: November 19, 2019
Phase: Phase 3
Study type: Interventional

Primary Objective: - To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: - To evaluate the efficacy of BIVV001 as a prophylaxis treatment. - To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. - To evaluate BIVV001 consumption for the prevention and treatment of bleeding episodes. - To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. - To evaluate the effect of BIVV001 prophylaxis on Quality of Life outcomes. - To evaluate the efficacy of BIVV001 for perioperative management. - To evaluate the safety and tolerability of BIVV001 treatment. - To assess the pharmacokinetics (PK) of BIVV001 based on the 1-stage activated partial thromboplastin time (aPTT) and 2-stage chromogenic coagulation factor VIII (FVIII) activity assays.

NCT ID: NCT04133883 Completed - Hemophilia A Clinical Trials

Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination

A-MOVE
Start date: January 13, 2020
Phase: N/A
Study type: Interventional

This low interventional study aims to describe if and how the haemophilia treatment management decisions are impacted by a systematic joint examination (ultrasound, functional, physical) in patients with haemophilia A in France.

NCT ID: NCT04131920 Completed - Hemophilia A Clinical Trials

Handheld Ultrasound (HHUS) for Home Use in Hemophilia

HHUS
Start date: October 1, 2019
Phase:
Study type: Observational

This is a study in 3 phases that will assess the feasibility and utility of handheld home ultrasound (HHUS) in a patient's home to assess whether a painful episode in the elbow, knee or ankle is a bleed or not.

NCT ID: NCT04085458 Completed - Hemophilia A Clinical Trials

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Start date: September 23, 2019
Phase: Phase 4
Study type: Interventional

The goal of this study is to give gather more information on how safe and well Jivi works in patients with severe hemophilia A. Jivi has been approved by various regulatory agencies, including the FDA, Health Canada, Japanese Health Authority and the European Medicinal Agency. 25 patients will be enrolled and will stay for 1 to 2 years in this study depending on their treatment frequency. Researcher will monitor during the course of the study whether patients are developing antibodies (a protein made by the body in response to the drug) affecting the effectiveness of Jivi. In addition information on bleedings and patient's wellbeing will be collected.